Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 7711 results

  1. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777

    Awaiting development [GID-TA11292] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Subcutaneous efgartigmod for treating generalised myasthenia gravis TS ID 11835

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730

    Awaiting development [GID-TA11105] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria TS ID 11832

      Status ...

    Technology appraisal guidance
    Topic selection

  5. WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467

    Awaiting development [GID-TA11305] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Perioperative care

    Awaiting development [GID-QS10094] Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome TS ID 11820

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years TS ID 10350

      Status ...

    Technology appraisal guidance
    Topic selection

  9. Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years TS ID 11805

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Remimazolam for general anaesthesia [ID3796]

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over TS ID 10761

      Status ...

    Technology appraisal guidance
    Topic selection

  12. Vilobelimab for treating COVID-19 TS ID 11815

    Awaiting development [GID-TA11227] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Sabizabulin for treating COVID-19 TS ID 11814

    Awaiting development [GID-TA11226] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830

    Awaiting development [GID-TA11251] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome TS ID 9998

      Status ...

    Technology appraisal guidance
    Topic selection